Vyant Bio, Inc. (VYNT)

OTCMKTS: VYNT · Delayed Price · USD
0.170
+0.003 (1.80%)
Sep 29, 2023, 12:20 PM EDT - Market closed
Market Cap 1.08M
Revenue (ttm) 666,000
Net Income (ttm) -28.71M
Shares Out 6.33M
EPS (ttm) -4.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,080
Open 0.177
Previous Close 0.167
Day's Range 0.170 - 0.180
52-Week Range 0.141 - 3.000
Beta 0.55
Analysts Hold
Price Target n/a
Earnings Date Aug 29, 2023

About VYNT

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 5, 2013
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol VYNT
Full Company Profile

Financial Performance

In 2022, Vyant Bio's revenue was $666,000, a decrease of -41.99% compared to the previous year's $1.15 million. Losses were -$22.69 million, -50.78% less than in 2021.

Financial Statements

News

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Speci...

2 days ago - GlobeNewsWire

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

—Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific Tea...

2 months ago - PRNewsWire

Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration

CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improv...

5 months ago - GlobeNewsWire

Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration

CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to impr...

5 months ago - GlobeNewsWire

Oxford Nanopore and 4bases Announce Collaboration to Combine Nanopore Sequencing Devices and 4bases Kits to Support Rapid, High-accuracy Analyses in Human and Cancer Genetics, with a First Target of Same-day BRCA1 and BRCA2 Analysis

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies plc (Oxford Nanopore) and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, today announc...

6 months ago - Business Wire

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force

Continu ing to E xplore S trategic A lternatives

8 months ago - GlobeNewsWire

Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives

CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

9 months ago - GlobeNewsWire

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience

“Targeting specific functional rescue in a Rett patient cortical organoid disease model”

11 months ago - GlobeNewsWire

Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

11 months ago - GlobeNewsWire

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation

CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

11 months ago - GlobeNewsWire

Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala'

Charity Event to Drive Awareness and Support Rett Families Around the World

11 months ago - GlobeNewsWire

Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary

~ Reaction Biology Acquire s the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~

11 months ago - GlobeNewsWire

Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022

P latform and P oster Presentation s on Vyant Bio's Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD)

1 year ago - GlobeNewsWire

Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022

- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases

1 year ago - GlobeNewsWire

Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

1 year ago - GlobeNewsWire

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

Conference Call and Webcast Today at 4:30 pm ET

1 year ago - GlobeNewsWire

Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

1 year ago - GlobeNewsWire

Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast

CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

1 year ago - GlobeNewsWire

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

1 year ago - GlobeNewsWire

Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference

Cherry Hill, New Jersey--(Newsfile Corp. - August 3, 2022) - Vyant Bio, Inc. (NASDAQ: VYNT) ("Vyant Bio" or "Company") is an innovative biotechnology company reinventing drug discovery for complex neu...

1 year ago - Newsfile Corp

Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services

CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

1 year ago - GlobeNewsWire

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights

Conference Call and Webcast Today at 4:30 pm ET

1 year ago - GlobeNewsWire

Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022

CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopme...

1 year ago - GlobeNewsWire

Vyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering Conference

CHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopment...

1 year ago - GlobeNewsWire